Abstract: A method of treating an angiogenesis related disease or disorder in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which regulates an amount of apolipoprotein B (ApoB), and/or an ability of ApoB to transcriptionally control vascular endothelial growth factor receptor 1 (VEGFR1).
Type:
Grant
Filed:
November 27, 2012
Date of Patent:
April 11, 2017
Assignee:
Yeda Research and Development Co. Ltd.
Inventors:
Karina Yaniv, Inbal Avraham-Davidi, Yogev Sela
Abstract: The disclosure relates to the field of cardiovascular diseases. In particular, immunoglobulin single variable domains directed against macrophage mannose receptor (MMR) are provided that can be used in the diagnosis, prognosis and/or monitoring of cardiovascular diseases or as therapeutics. Also, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are useful at different stages of cardiovascular diseases, including post-infarction cardiovascular events. Further, the anti-macrophage mannose receptor (MMR) immunoglobulin single variable domains of the disclosure are particularly useful for the in vivo targeting and/or imaging of vulnerable atherosclerotic plaques.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
April 11, 2017
Assignees:
VIB VZW, Vrije Universiteit Brussel
Inventors:
Patrick De Baetselier, Geert Raes, Steve Schoonooghe, Jens De Vos, Tony Lahoutte, Nick Devoogdt, Sophie Hernot, Gezim Bala, Simon Tierens
Abstract: A mouse monoclonal antibody for antagonizing and inhibiting binding of a vascular endothelial growth factor (VEGF) and its receptor (VEGF-R), and a heavy chain variable region and light chain variable region amino acid sequence thereof. Also disclosed are a humanized preparation process of the antibody and a heavy chain variable region and light chain variable region amino acid sequence of the humanized antibody. The humanized antibody or its derivative can act as an ingredient of a pharmaceutical composition or be prepared into a suitable pharmaceutical preparation, is administered alone or in combination with a chemotherapy drug or other treatment means, and is used in broad-spectrum treatment of various solid tumors such as colon cancer, breast cancer and rhabdomyosarcoma.
Abstract: A method according to an embodiments includes administering at least two Cyclic Variations in Altitude Condition (CVAC) sessions to a mammal disposed in a pressure vessel unit. The at least two CVAC sessions each have a duration of at least twenty minutes. The at least two CVAC sessions each include a start point of ambient pressure at a delivery site, an end point of ambient pressure at the delivery site, and a plurality of atmospheric pressure targets executed between the start point and the end point. The administering is configured to treat at least one of loss of sensation and chronic pain.
Abstract: The present invention relates to a compound which is an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression for use in the treatment or the prevention of aneurysm. In another embodiment, the invention relates to a pharmaceutical composition for use in the treatment or the prevention of aneurysm comprising an antagonist of IL-1 beta or an inhibitor of IL-1 beta expression.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
February 21, 2017
Assignees:
INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Paris Descartes
Abstract: Agents, compositions, and medicaments that reduce interactions between muscle specific kinase receptor (MuSK) and pathogenic immunoglobulin G4 (IgG4) antibodies specific for the first Ig-like domain of MuSK and methods and uses thereof to reduce such interactions are encompassed herein. Also encompassed are screening assays to identify inhibitors of these pathogenic antibodies, particularly those that reduce binding to MuSK. Agents identified using the screening assays described herein are envisioned for use as therapeutics, alone or in compositions or in medicaments, to improve motor function in subjects afflicted MuSK-MG.
Type:
Grant
Filed:
September 15, 2014
Date of Patent:
February 21, 2017
Assignees:
New York University, Leiden University Medical Center
Inventors:
Steven J. Burden, Wei Zhang, Maartje Huijbers, Johannes J. Verschuuren, Silvère M. van der Maarel
Abstract: The invention is directed, in part, to the use of gelsolin to diagnose, monitor, and treat subjects with renal failure (e.g., chronic renal failure subjects on dialysis).
Type:
Grant
Filed:
January 23, 2009
Date of Patent:
February 21, 2017
Assignees:
The Brigham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc., The General Hospital Corporation
Inventors:
Ravi Thadhani, Thomas P. Stossel, Po-Shun Lee, Ananth Karumanchi
Abstract: Provided herein are methods for the treatment of chronic kidney disease and proteinuria and for the diagnosis of chronic kidney disease and monitoring the effects of treatment on the progression of chronic kidney disease and proteinuria based on unexpected roles for the SLIT-ROBO signaling pathway in the regulation of podocyte F-actin cytoskeleton and foot process structure in the kidney.
Type:
Grant
Filed:
January 4, 2013
Date of Patent:
February 21, 2017
Assignee:
Boston Medical Center Corporation
Inventors:
Weining Lu, Xueping Fan, David J. Salant
Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
June 18, 2014
Date of Patent:
February 7, 2017
Assignee:
NOVARTIS AG
Inventors:
Kurt Alex Heldwein, Jennifer Brogdon, William Dole, John Trauger, Yuting Tang, Julia Neugebauer, Annika Schmid
Abstract: The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used.
Abstract: Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or avoid exercise therapy, determining whether a subject having a cardiovascular disease should continue, discontinue, or avoid exercise therapy, reducing the risk of an adverse outcome (e.g., death) in a subject having a cardiovascular disease, and predicting the efficacy of exercise therapy in a subject having a cardiovascular disease. These methods include determining a level of soluble ST2 in a subject.
Abstract: The present invention relates to the therapeutic use of activators of the zinc finger protein GLI3 in diseases that are associated with reduced Hedgehog signaling in hepatocytes, in particular Polycystic ovary syndrome, Steatosis hepatis, Steatohepatitis and/or Adipositas. The invention further relates to methods of treating an individual with said activator, a pharmaceutical composition comprising said activator and the use of said activator as food supplement.
Abstract: Provided herein are methods for reducing, inhibiting, suppressing and/or delaying atherosclerotic plaque growth or neovascularization in a subject having atherosclerosis, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to Semaphorin-4D (SEMA4D) or to its high affinity Plexin-B1 receptor.
Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
June 18, 2014
Date of Patent:
December 6, 2016
Assignee:
Novartis AG
Inventors:
Kurt Alex Heldwein, Igor Splawski, Jennifer Brogdon, Joshua Goldstein, William Dole, John Trauger, Chonghui Zhang
Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
Type:
Grant
Filed:
January 14, 2014
Date of Patent:
November 29, 2016
Assignees:
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Inventors:
Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.
Abstract: Methods of using an ETB receptor agonist, such as IRL-1620, for the treatment of stroke or cerebrovascular accidents are disclosed. The ETB receptor agonist is used alone or in combination with a second agent useful in the treatment of stroke or other cerebrovascular accident.
Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
Type:
Grant
Filed:
March 23, 2005
Date of Patent:
October 11, 2016
Assignee:
Boehringer Ingelheim Vetmedica GmbH
Inventors:
Juergen Daemmgen, Olaf Joens, Rainer Kleemann